Liver damage in bleomycin-induced pulmonary fibrosis in mice
- 142 Downloads
Pulmonary fibrosis is an emerging disease with a poor prognosis and high mortality rate that is even surpassing some types of cancer. This disease has been linked to the concomitant appearance of liver cirrhosis. Bleomycin-induced pulmonary fibrosis is a widely used mouse model that mimics the histopathological and biochemical features of human systemic sclerosis, an autoimmune disease that is associated with inflammation and expressed in several corporal systems as fibrosis or other alterations. To determine the effects on proliferation, redox and inflammation protein expression markers were analyzed by immunohistochemistry. Analyses showed a significant increase in protein oxidation levels by lipoperoxidation bio-products and in proliferation and inflammation processes. These phenomena were associated with the induction of the redox status in mice subjected to 100 U/kg bleomycin. These findings clearly show that the bleomycin model induces histopathological alterations in the liver and partially reproduces the complexity of systemic sclerosis. Our results using the bleomycin-induced pulmonary fibrosis model provide a protocol to investigate the mechanism underlying the molecular alteration found in the liver linked to systemic sclerosis.
KeywordsLiver damage Bleomycin Multiorgan disease Reactive oxygen species Proliferation
The authors want to express their gratitude to the UPEAL-CINVESTAV staff and American Journal Experts (AJE). This work was supported by the Consejo Nacional de Ciencia y Tecnología (CONACYT), 270189-2016; from RBH, 178558 from SVT, 287162 from RBH, 290194 from VRVG, and Cátedra-CONACYT 2499-2014 (Molecular studies for the treatment of scleroderma) from RBH, VRVG, and JA.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- Eslami A, Mathur AD, Jha KK, Wang H (2018) Acute liver failure secondary to ABVD use. BMJ Case RepGoogle Scholar
- Fischer R, Maier O (2015) Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. Oxidative Med Cell Longev, 610813Google Scholar
- Galli A, Svegliati-Baroni G, Ceni E, Milani S, Ridolfi F, Salzano R, Tarocchi M, Grappone C, Pellegrini G, Benedetti A, Surrenti C, Casini A (2005) Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology 41:1074–1084PubMedGoogle Scholar
- Grygiel-Gorniak B, Puszczewicz M (2014) Oxidative damage and antioxidative therapy in systemic sclerosis. Mediat Inflamm, 389582Google Scholar
- Inghilleri S, Morbini P, Campo I, Zorzetto M, Oggionni T, Pozzi E, Luisetti M (2011) Factors influencing oxidative imbalance in pulmonary fibrosis: an immunohistochemical study. Pulm Med, 421409Google Scholar
- Islam MA, Alam F, Solayman M, Khalil MI, Kamal MA, Gan SH (2016) Dietary phytochemicals: natural swords combating inflammation and oxidation-mediated degenerative diseases. Oxidative Med Cell Longev, 5137431Google Scholar
- Joensuu H, Söderström KO, Nikkanen V (1986) Fatal necrosis of the liver during ABVD chemotherapy for Hodgkin’s disease. A case report. Cancer t 1 58(7):1437–1440Google Scholar
- Marie I, Levesque H, Tranvouez JL, Francois A, Riachi G, Cailleux N, Courtois H (2001) Autoimmune hepatitis and systemic sclerosis: a new overlap syndrome? Rheumatology (Oxford) 40:102–106Google Scholar
- Marí-Alfonso B, Simeon-Aznar CP, Guillen-Del Castillo A, Rubio-Rivas M, Trapiella-Martinez L, Todoli-Parra JA, Rodriguez Carballeira M, Marin-Ballve A, Iniesta-Arandia N et al (2017) Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: characteristics and survival of patients from the Spanish RESCLE Registry. Semin Arthritis Rheum S0049-0172(17):30288–30283Google Scholar
- Matucci Cerinic M, Kahaleh MB (2002) Beauty and the beast. The nitric oxide paradox in systemic sclerosis. Rheumatology (Oxford) 41:843–847Google Scholar
- Nuver J, Lutke Holzik MF, van Zweeden M, Hoekstra HJ, Meijer C, Suurmeijer AJ, Groen HJ, Hofstra RM, Sluiter WJ, Groen H, Sleijfer DT, Gietema JA (2005) Genetic variation in the bleomycin hydrolase gene and bleomycin-induced pulmonary toxicity in germ cell cancer patients. Pharmacogenet Genomics 15:399–340PubMedGoogle Scholar
- Tashiro M, Izumikawa K, Yoshioka D, Nakamura S, Kurihara S, Sakamoto N, Seki M, Kakeya H, Yamamoto Y, Yanagihara K, Mukae H, Hayashi T, Fukushima K, Tashiro T, Kohno S (2008) Lung Fibrosis 10 Years after Cessation of Bleomycin Therapy. Tohoku J Exp Med 216(1):77–80. https://doi.org/10.1620/tjem.216.77 PubMedGoogle Scholar
- Umezawa H, Maeda K, Takeuchi T, Okami Y (1966) New antibiotics, bleomycin A and B. J Antibiot (Tokyo) 19:200–209Google Scholar
- Yahyapour R, Motevaseli E, Rezaeyan A, Abdollahi H, Farhood B, Cheki M, Rezapoor S, Shabeeb D, Musa AE, Najafi M, Villa V (2018) Reduction-oxidation (redox) system in radiation-induced normal tissue injury: molecular mechanisms and implications in radiation therapeutics. Clin Transl Oncol 20:975–988PubMedGoogle Scholar
- Zmuc J, Gasljevic G, Sersa G, Edhemovic I, Boc N, Seliskar A, Plavec T, Brloznik M, Milevoj N, Brecelj E, Kos B, Izlakar J, Jarm T, Snoj M, Stukelj M, Miklavcic D, Cemazar M (2019) Large liver blood vessels and bile ducts are not damaged by electrochemotherapy with bleomycin in pigs. Sci Rep 9(1):3649PubMedPubMedCentralGoogle Scholar